GLAUKOS Corp — fact timeline

GLAUKOS Corp reported the first quarter ended March 31, 2026 results: revenue $150.6 million, net income $19.8 million, EPS ($0.34) per diluted share. Guidance raised.

“of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: • Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. • Glaucoma record net sales of $129.3 million in Q1 2026”

GLAUKOS Corp reported first quarter ended March 31, 2024 results: revenue $85.6 million, net income ($40.8 million), EPS ($0.82) per diluted share. Guidance raised.

“of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: ● Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. ● Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. ● Corneal Health net sales of $18.4 million in Q1”

GLAUKOS Corp reported the fourth quarter and full year ended December 31, 2023 results: revenue $82.4 million, net income $36.8 million, EPS ($0.75) per diluted share. Guidance reaffirmed.

“disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: ● Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year on a constant currency basis. ● Glaucoma net sales of $60.6 million in Q4 2023 increased 15%”

GLAUKOS Corp reported the fiscal year ended December 31, 2023 results: revenue in excess of $313 million.

“Preliminary and unaudited total net sales for the fourth quarter and full year of 2023 are expected to be in excess of $81 million and $313 million, respectively.”

GLAUKOS Corp reported the fourth quarter ended December 31, 2023 results: revenue in excess of $81 million.

“Preliminary and unaudited total net sales for the fourth quarter and full year of 2023 are expected to be in excess of $81 million and $313 million, respectively.”

GLAUKOS Corp reported third quarter ended September 30, 2023 results: revenue $78.0 million, net income ($30.4 million, or ($0.63) per diluted share). Guidance raised.

“of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: · Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a reported basis and 9% year-over-year on a constant currency basis. · Glaucoma net sales of $58.3 million in Q3 2023 increased 9%”

GLAUKOS Corp reported 2023 results: revenue $304 million to $308 million. Guidance raised.

“Raised 2023 net sales guidance to $304 million to $308 million, compared to $295 million to $300 million previously.”

GLAUKOS Corp reported the second quarter ended June 30, 2023 results: revenue $80.4 million, net income $32.8 million, EPS ($0.68) per diluted share.

“Net sales in the second quarter of 2023 of $80.4 million increased 11%, compared to $72.7 million in the same period in 2022. Gross margin for the second quarter of 2023 was approximately 75%, compared to approximately 75% in the same period in 2022. Non-GAAP gross margin for the second quarter of 2023 was approximately 82%, compared to approximately 83% in the same period in 2022. Selling, general and administrative (SG&A) expenses for the second quarter of 2023 increased 6% to $53.1 million, compared to $49.9 million in the same period in 2022. Non-GAAP SG&A expenses for the second quarter of 2023 increased 7% to $52.4 million, compared to $49.0 million in the same period in 2022. GAAP and non-GAAP research and development (R&D) expenses for the second quarter of 2023 increased 5% to $33.2 million, compared to $31.7 million in the same period in 2022. ​ ​ 1 Loss from operations in the second quarter of 2023 was $29.1 million, compared to operating loss of $36.8 million in the second”

GLAUKOS Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022 at the 2023-06-01 meeting.

“Proposal 3 . The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022: 1, ​ ​ ​ ​ For Against Abstain 43,725,937 ​ 145,925 ​ 21,838”

GLAUKOS Corp shareholders approved Non-binding advisory vote regarding approval of the compensation of the Company’s named executive officers at the 2023-06-01 meeting.

“Proposal 2 . The non-binding advisory vote regarding approval of the compensation of the Company’s named executive officers: ​ ​ ​ ​ ​ ​ ​ For Against Abstain Broker Non-Votes 37,101,296 ​ 3,742,568 ​ 30,094 ​ 3,019,742”

GLAUKOS Corp shareholders approved Election of two Class II directors to hold office until the 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified at the 2023-06-01 meeting.

“Proposal 1 . The election of two Class II directors to hold office until the 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified: ​ ​ ​ ​ ​ ​ ​ ​ ​ For Withheld Broker Non-Votes Denice M. Torres ​ 29,021,555 ​ 11,852,403 ​ 3,019,742 Aimee S. Weisner ​ 39,492,847 ​ 1,381,111 ​ 3,019,742”

GLAUKOS Corp reported the first quarter ended March 31, 2023 results: revenue $73.9 million, net income $34.6 million, EPS ($0.72) per diluted share. Guidance raised.

“of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: ● Net sales of $73.9 million in Q1 2023 increased 9% year-over-year on a reported basis and 11% year-over-year on a constant currency basis. ● Glaucoma net sales of $56.2 million in Q1 2023 increased 9%”

GLAUKOS Corp reported fiscal year 2023 results: revenue $290 million to $295 million. Guidance initiated.

“The company expects 2023 net sales to be in the range of $290 million to $295 million based on the latest foreign currency exchange rates.”

GLAUKOS Corp reported fiscal year ended December 31, 2022 results: revenue $282.9 million, net income $99.2 million, EPS ($2.09) per diluted share.

“Net sales in 2022 of $282.9 million declined 4% on a reported basis, or 2% on a constant currency basis, compared to $294.0 million in 2021.”

GLAUKOS Corp reported fourth quarter ended December 31, 2022 results: revenue $71.2 million, net income $31.5 million, EPS ($0.66) per diluted share.

“Net sales in the fourth quarter of 2022 of $71.2 million declined 3% on a reported basis, or were flat on a constant currency basis, compared to $73.2 million in the same period in 2021.”

GLAUKOS Corp: 修订公司细则，纳入通用代理规则、更新提前通知要求、休会程序、代理卡颜色、股东名单检查、会议推迟等。 (effective 2022-12-15).

“On December 15, 2022, the Board of Directors (the “Board”) of Glaukos Corporation (the “Company”) approved amendments to the Company’s Amended and Restated Bylaws (the “Bylaws”). In addition to purely ministerial or minor conforming changes, these amendments principally provide for the following: ● Advance Notice—Universal Proxy . The amendments incorporate the new universal proxy rule (Rule 14a-19) promulgated by the U.S. Securities and Exchange Commission (“SEC”) into the advance notice provisions applicable to director nominations in Section 2.4 of the Bylaws. A new provision has also been added to Section 2.4 of the Bylaws to require a stockholder providing advance notice of director nominations to provide reasonable evidence, within 5 business days prior to the meeting, that it has met the universal proxy requirements of Rule 14a-19 and to provide that if a stockholder does not comply with the requirements of the SEC’s universal proxy rule, including soliciting at least 67% of the”

GLAUKOS Corp reported third quarter ended September 30, 2022 results: revenue $71.3 million, net income $27.6 million, EPS ($0.58) per diluted share. Guidance raised.

“of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2022. Key highlights include: ● Net sales of $71.3 million in Q3 2022. ● Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million in Q3 2022. ● Gross margin of approximately 76% and non-GAAP gross margin of”

Alex R. Thurman was appointed as Senior Vice President, Chief Financial Officer at GLAUKOS Corp.

“Alex R. Thurman, the Company’s current Vice President, Finance, has been appointed as the Company’s Senior Vice President, Chief Financial Officer, which appointment will take effect on April 1, 2022.”

Joseph E. Gilliam was appointed as President and Chief Operating Officer at GLAUKOS Corp.

“Joseph E. Gilliam, the Company’s current Chief Financial Officer and Senior Vice President, Corporate Development, has been appointed as the Company’s President and Chief Operating Officer, which appointment will take effect on April 1, 2022.”

Chris M. Calcaterra changed role as EVP, Global Commercial Operations at GLAUKOS Corp.

“Chris M. Calcaterra will step down from his role as the Company’s Chief Operating Officer and will transition to the position of EVP, Global Commercial Operations, effective April 1, 2022.”

Mark J. Foley was appointed as Lead Independent Director at GLAUKOS Corp.

“the independent members of the Board appointed Mark J. Foley, who has served as a member of the Board since 2014 and is the Chair of the Compensation Committee, as the Board’s Lead Independent Director effective December 31, 2021.”

Thomas W. Burns was appointed as Chairman of the Board at GLAUKOS Corp.

“the Board, upon the recommendation of the Compensation Committee, appointed Thomas W. Burns, the Company’s President and Chief Executive Officer and a director on the Board since 2002, to serve as the Chairman of the Board of the Company effective upon Dr. Link’s retirement on December 31, 2021.”

William J. Link retired as Chairman of the Board at GLAUKOS Corp.

“On December 16, 2021, William J. Link, Ph.D., informed Glaukos Corporation (the “Company”) that he intends to retire from the Company’s Board of Directors (the “Board”) effective December 31, 2021.”